{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:35:53Z","timestamp":1789785353436,"version":"4.0.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T00:00:00Z","timestamp":1524009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40262-018-0662-5","type":"journal-article","created":{"date-parts":[[2018,4,18]],"date-time":"2018-04-18T01:45:33Z","timestamp":1524015933000},"page":"63-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Pharmacokinetics and Pharmacodynamics of Once-Weekly Somapacitan in Children and Adults: Supporting Dosing Rationales with a Model-Based Analysis of Three Phase I Trials"],"prefix":"10.1007","volume":"58","author":[{"given":"Rasmus Vestergaard","family":"Juul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H\u00f8jby","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Agers\u00f8","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rune Viig","family":"Overgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,18]]},"reference":[{"key":"662_CR1","unstructured":"Consensus guidelines for the diagnosis and treatment of growth hormone (GH) deficiency in childhood and adolescence: summary statement of the GH Research Society. GH Research Society. J Clin Endocrinol Metab. 2000;85(11):3990\u20133."},{"issue":"6","key":"662_CR2","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1210\/jc.2011-0179","volume":"96","author":"ME Molitch","year":"2011","unstructured":"Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587\u2013609.","journal-title":"J Clin Endocrinol Metab."},{"key":"662_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.3389\/fendo.2013.00064","volume":"4","author":"ML Reed","year":"2013","unstructured":"Reed ML, Merriam GR, Kargi AY. Adult growth hormone deficiency\u2014benefits, side effects, and risks of growth hormone replacement. Front Endocrinol. 2013;4:64.","journal-title":"Front Endocrinol."},{"issue":"6","key":"662_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000452150","volume":"86","author":"A Grimberg","year":"2016","unstructured":"Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86(6):361\u201397.","journal-title":"Horm Res Paediatr."},{"issue":"2","key":"662_CR5","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/s11102-007-0027-9","volume":"10","author":"CE Higham","year":"2007","unstructured":"Higham CE, Jostel A, Trainer PJ. IGF-I measurements in the monitoring of GH therapy. Pituitary. 2007;10(2):159\u201363.","journal-title":"Pituitary."},{"issue":"5","key":"662_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487\u201397.","journal-title":"N Engl J Med."},{"issue":"18","key":"662_CR7","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.12968\/bjon.2012.21.18.1091","volume":"21","author":"C Acerini","year":"2012","unstructured":"Acerini C, Albanese A, Casey A, Denvir L, Jones J, Mathew V, et al. Initiating growth hormone therapy for children and adolescents. Br J Nurs. 2012;21(18):1091\u20137.","journal-title":"Br J Nurs."},{"issue":"3","key":"662_CR8","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/cen.12240","volume":"79","author":"P Cawley","year":"2013","unstructured":"Cawley P, Wilkinson I, Ross RJ. Developing long-acting growth hormone formulations. Clin Endocrinol (Oxf). 2013;79(3):305\u20139.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"8","key":"662_CR9","doi-asserted-by":"publisher","first-page":"929","DOI":"10.4158\/EP171786.OR","volume":"23","author":"F Bagnasco","year":"2017","unstructured":"Bagnasco F, Di Iorgi N, Roveda A, Gallizia A, Haupt R, Maghnie M. Prevalence and correlates of adherence in children and adolescents treated with growth hormone: a multicenter Italian study. Endocr Pract. 2017;23(8):929\u201341.","journal-title":"Endocr Pract."},{"issue":"6","key":"662_CR10","doi-asserted-by":"publisher","first-page":"C1","DOI":"10.1530\/EJE-16-0111","volume":"174","author":"JS Christiansen","year":"2016","unstructured":"Christiansen JS, Backeljauw PF, Bidlingmaier M, Biller BM, Boguszewski MC, Casanueva FF, et al. Growth Hormone Research Society perspective on the development of long-acting growth hormone preparations. Eur J Endocrinol. 2016;174(6):C1\u20138.","journal-title":"Eur J Endocrinol."},{"key":"662_CR11","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ghir.2017.05.006","volume":"35","author":"P Thygesen","year":"2017","unstructured":"Thygesen P, Andersen HS, Behrens C, Fels JJ, Norskov-Lauritsen L, Rischel C, et al. Nonclinical pharmacokinetic and pharmacodynamic characterisation of somapacitan: a reversible non-covalent albumin-binding growth hormone. Growth Horm IGF Res. 2017;35:8\u201316.","journal-title":"Growth Horm IGF Res."},{"key":"662_CR12","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.ejps.2016.02.019","volume":"86","author":"B Vestergaard","year":"2016","unstructured":"Vestergaard B, Thygesen P, Kreilgaard M, Fels JJ, Lykkesfeldt J, Agerso H. The kidneys play a central role in the clearance of rhGH in rats. Eur J Pharm Sci. 2016;86:29\u201333.","journal-title":"Eur J Pharm Sci."},{"issue":"4","key":"662_CR13","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1111\/cen.13409","volume":"87","author":"T Battelino","year":"2017","unstructured":"Battelino T, Rasmussen MH, De Schepper J, Zuckerman-Levin N, Gucev Z, Savendahl L. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: a randomized dose-escalation trial. Clin Endocrinol (Oxf). 2017;87(4):350\u20138.","journal-title":"Clin Endocrinol (Oxf)."},{"issue":"11","key":"662_CR14","doi-asserted-by":"publisher","first-page":"E1819","DOI":"10.1210\/jc.2014-1702","volume":"99","author":"MH Rasmussen","year":"2014","unstructured":"Rasmussen MH, Braendholt Olsen MW, Alifrangis L, Klim S, Suntum M. A reversible albumin-binding growth hormone derivative is well-tolerated and possesses a potential once-weekly treatment profile. J Clin Endocrinol Metab. 2014;99(11):E1819\u201329.","journal-title":"J Clin Endocrinol Metab."},{"issue":"3","key":"662_CR15","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1210\/jc.2015-1991","volume":"101","author":"MH Rasmussen","year":"2016","unstructured":"Rasmussen MH, Janukonyte J, Klose M, Marina D, Tanvig M, Nielsen LF, et al. Reversible albumin-binding GH possesses a potential once-weekly treatment profile in adult growth hormone deficiency. J Clin Endocrinol Metab. 2016;101(3):988\u201398.","journal-title":"J Clin Endocrinol Metab."},{"key":"662_CR16","unstructured":"International Conference on Harmonisation. ICH harmonised tripartite guideline for good clinical practice. Geneva: ICH; 1996."},{"key":"662_CR17","unstructured":"World Medical Association. Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. Last amended by the 59th WMA General Assembly, Seoul, Republic of Korea. October 2008. \n                    https:\/\/www.wma.net\/wp-content\/uploads\/2016\/11\/DoH-Oct2008.pdf\n                    \n                  . Accessed 10 Apr 2018."},{"issue":"5","key":"662_CR18","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1210\/jc.2013-3059","volume":"99","author":"M Bidlingmaier","year":"2014","unstructured":"Bidlingmaier M, Friedrich N, Emeny RT, Spranger J, Wolthers OD, Roswall J, et al. Reference intervals for insulin-like growth factor-1 (IGF-i) from birth to senescence: results from a multicenter study using a new automated chemiluminescence IGF-I immunoassay conforming to recent international recommendations. J Clin Endocrinol Metab. 2014;99(5):1712\u201321.","journal-title":"J Clin Endocrinol Metab."},{"key":"662_CR19","volume-title":"NONMEM users guide. Parts I-VIII","author":"SL Beal","year":"2011","unstructured":"Beal SL, Boeckmann AJ, Sheiner LB. NONMEM users guide. Parts I-VIII. Hanover: ICON Development Solutions; 2011."},{"issue":"4","key":"662_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1208\/ps040427","volume":"4","author":"U W\u00e4hlby","year":"2002","unstructured":"W\u00e4hlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic-pharmacodynamic analysis. AAPS PharmSci. 2002;4(4):68\u201379.","journal-title":"AAPS PharmSci."},{"key":"662_CR21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-17-1073","author":"G Johannsson","year":"2018","unstructured":"Johannsson G, Feldt-Rasmussen U, Holme Hakonsson I, Biering H, Rodien P, Tahara S, et al. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial. Eur J Endocrinol. Epub. 2018. \n                    https:\/\/doi.org\/10.1530\/EJE-17-1073\n                    \n                  .","journal-title":"Eur J Endocrinol. Epub"},{"issue":"5","key":"662_CR22","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1136\/mp.54.5.311","volume":"54","author":"Z Laron","year":"2001","unstructured":"Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. Mol Pathol. 2001;54(5):311\u20136.","journal-title":"Mol Pathol."}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-018-0662-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0662-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-018-0662-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T10:31:16Z","timestamp":1568716276000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-018-0662-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,18]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["662"],"URL":"https:\/\/doi.org\/10.1007\/s40262-018-0662-5","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,18]]},"assertion":[{"value":"18 April 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Funding for this study was supplied by Novo Nordisk A\/S.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"RVJ, MHR, HA, and RVO are employees\/shareholders of Novo Nordisk A\/S.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}